Elicera Therapeutics AB (publ) (STO:ELIC)
Sweden · Delayed Price · Currency is SEK 2.945
-0.020 (-0.67%)
Aug 13, 2026, 5:29 PM CET
Elicera Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 10.64 | 10.86 | 7.13 | 11.23 | 1.28 | 0 | |
Revenue Growth | 146.66% | 52.28% | -36.52% | 777.23% | 217987.39% | - |
Gross Profit | 10.64 | 10.86 | 7.13 | 11.23 | 1.28 | 0 |
Selling, General & Admin | 25.63 | 28.8 | 24 | 28.31 | 20.63 | 13.11 |
Depreciation & Amortization Expenses | - | - | 0.01 | 0.01 | 0.01 | 0.01 |
Total Operating Expenses | 25.63 | 28.8 | 24.01 | 28.33 | 20.64 | 13.12 |
Operating Income | -14.99 | -17.94 | -16.88 | -17.1 | -19.36 | -13.12 |
Interest Income | 0.55 | 0.55 | 0.83 | 0.77 | 0.05 | - |
Interest Expense | -0.01 | -0.01 | -0.05 | -0.08 | -0.13 | -0 |
Total Non-Operating Income (Expense) | 0.54 | 0.54 | 0.77 | 0.7 | -0.08 | -0 |
Pretax Income | -14.45 | -17.41 | -16.11 | -16.4 | -19.44 | -13.12 |
Net Income | -14.45 | -17.41 | -16.11 | -16.4 | -19.44 | -13.12 |
Net Income to Common | -14.45 | -17.41 | -16.11 | -16.4 | -19.44 | -13.12 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 49 | 46 | 32 | 20 | 20 | 16 |
Shares Outstanding (Diluted) | 49 | 46 | 32 | 20 | 23 | 18 |
Shares Change | 2.92% | 45.01% | 59.89% | -15.31% | 30.38% | 419.69% |
EPS (Basic) | -0.29 | -0.38 | -0.51 | -0.83 | -0.98 | -0.82 |
EPS (Diluted) | -0.29 | -0.38 | -0.51 | -0.83 | -0.98 | -0.82 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -17.71 | -21.55 | -23.46 | -14.92 | -8.57 | -13.11 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.36 | -0.47 | -0.74 | -0.76 | -0.37 | -0.73 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -140.95% | -165.31% | -236.86% | -152.24% | -1512.51% | -2234990.00% |
Profit Margin | -135.88% | -160.35% | -226.01% | -146.02% | -1518.44% | -2235170.00% |
FCF Margin | -166.52% | -198.53% | -329.16% | -132.88% | -669.50% | -2233160.00% |
EBITDA | -14.99 | -17.94 | -16.87 | -17.08 | -19.35 | -13.11 |
EBITDA Margin | -140.95% | -165.31% | -236.70% | -152.13% | -1511.59% | -2232980.00% |
EBIT | -14.99 | -17.94 | -16.88 | -17.1 | -19.36 | -13.12 |
EBIT Margin | -140.95% | -165.31% | -236.86% | -152.24% | -1512.51% | -2234990.00% |